{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-113591","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.124535+00:00","generated_at":"2026-06-08T23:56:42.306712+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cognition Therapeutics reports Q3 net loss of $6.7M; updates on Alzheimer’s and DLB trials","bullets":["Net loss of $6.7M ($0.22 per share) in Q3 2023 vs $6.6M ($0.29 per share) in Q3 2022.","Cash and equivalents $33.0M; total grant funds $74.3M from NIA; cash runway through Nov 2024.","Phase 2 SHINE Alzheimer’s topline results expected mid-2024; SHIMMER DLB data also mid-2024.","START trial initiated allowing lecanemab combo therapy; MAGNIFY dry AMD study dosing started.","R&D expenses $11.7M (up 41% YoY); G&A $3.1M (down 30% YoY)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-113591","json":"https://secwatch.observer/filing/0001104659-23-113591.json","markdown":"https://secwatch.observer/filing/0001104659-23-113591.md","text":"https://secwatch.observer/filing/0001104659-23-113591.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465923113591/0001104659-23-113591-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465923113591/tm2329528d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T23:56:42.306712+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3eb49fbaa2e19b5f24979d72b7265b3223f86952","claim":"COGNITION THERAPEUTICS INC reported third quarter ended September 30, 2023 results: net income net loss of $6.7 million, EPS $(0.22) per basic and diluted share.","evidence_excerpt":"The Company reported a net loss of $6.7 million or $(0.22) per basic and diluted share for the third quarter ended September 30, 2023, compared to a net loss of $6.6 million or $(0.29) per basic and diluted share during the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465923113591/0001104659-23-113591-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"net loss of $6.7 million"},{"label":"EPS","value":"$(0.22) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}